Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
3 May 24
DEFA14A
Additional proxy soliciting materials
3 May 24
DEF 14A
Definitive proxy
3 May 24
10-Q
2024 Q1
Quarterly report
2 May 24
8-K
Aurinia Pharmaceuticals Reports First Quarter 2024 Financial and Operational Results
2 May 24
10-K/A
2023 FY
Annual report (amended)
29 Apr 24
8-K
Departure of Directors or Certain Officers
29 Feb 24
10-K
2023 FY
Annual report
15 Feb 24
8-K
Aurinia Discloses 2023 Year-End Financial and Operational Results, Announces Corporate Actions Focused on Enhancing Shareholder Value
15 Feb 24
8-K
Aurinia Provides Preliminary Unaudited Fourth Quarter and Full-year 2023 Net Revenue Results
5 Jan 24
10-Q
2023 Q3
Quarterly report
2 Nov 23
8-K
Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2023 Financial and Operational Results
2 Nov 23
8-K
Aurinia Board of Directors Appoints Dr. Robert T. Foster as New Board Director
21 Sep 23
8-K
Dr. Daniel G. Billen appointed Chair of the Board of Directors
21 Aug 23
10-Q
2023 Q2
Quarterly report
3 Aug 23
8-K
Aurinia Pharmaceuticals Reports Second Quarter and Six Months 2023 Financial and Operational Results
3 Aug 23
PX14A6G
Letter to shareholders
6 Jul 23
8-K
Aurinia Board of Directors Announces Exploration of Strategic Alternatives to Maximize Shareholder Value
3 Jul 23
PX14A6G
Letter to shareholders
1 Jun 23
S-8
Registration of securities for employees
26 May 23
8-K
Submission of Matters to a Vote of Security Holders
17 May 23
PX14A6G
Letter to shareholders
17 May 23
PX14A6G
Letter to shareholders
11 May 23
DEFA14A
Additional proxy soliciting materials
8 May 23
PX14A6G
Letter to shareholders
5 May 23
10-Q
2023 Q1
Quarterly report
4 May 23
8-K
Aurinia Pharmaceuticals Reports First Quarter 2023 Financial and Operational Results
4 May 23
PX14A6G
Letter to shareholders
3 May 23
DEFA14A
Additional proxy soliciting materials
2 May 23
DEFA14A
Additional proxy soliciting materials
28 Apr 23
PX14A6G
Letter to shareholders
26 Apr 23
DEF 14A
Definitive proxy
18 Apr 23
8-K
Aurinia Pharmaceuticals Announces Promising Topline Data from Renal Biopsy Sub-study of the AURORA Trial
5 Apr 23
8-K
Other Events
13 Mar 23
10-K
2022 FY
Annual report
28 Feb 23
8-K
Aurinia Reports Fourth Quarter and Full Year 2022 Financial Results and Company Updates
28 Feb 23
8-K
Other Events
27 Jan 23
8-K
Aurinia Provides Preliminary Unaudited Fourth Quarter and Full-year 2022 Net Revenue Results
9 Jan 23
8-K
Other Events
3 Jan 23
10-Q
2022 Q3
Quarterly report
3 Nov 22
Latest ownership filings
SC 13D/A
ILJIN SNT Co., Ltd.
20 Mar 24
4
Peter Greenleaf
7 Mar 24
4
Joseph M Miller
7 Mar 24
4
Matthew Maxwell Donley
7 Mar 24
4
Scott Michael Habig
7 Mar 24
4
Stephen P. Robertson
7 Mar 24
4
Volker Knappertz
29 Feb 24
4
Volker Knappertz
22 Feb 24
4
Scott Michael Habig
22 Feb 24
4
Matthew Maxwell Donley
22 Feb 24
4
Stephen P. Robertson
22 Feb 24
4
Joseph M Miller
22 Feb 24
4
Peter Greenleaf
22 Feb 24
4/A
Stephen P. Robertson
22 Feb 24
4/A
Joseph M Miller
22 Feb 24
4/A
Peter Greenleaf
22 Feb 24
SC 13G
ARMISTICE CAPITAL, LLC
14 Feb 24
SC 13G/A
BlackRock Inc.
12 Feb 24
4
Robert T Foster
22 Sep 23
3
Robert T Foster
22 Sep 23
4
Jeffrey Allen Bailey
21 Aug 23
3
Jeffrey Allen Bailey
21 Aug 23
4
Karen L. Smith
21 Aug 23
3
Karen L. Smith
21 Aug 23
4
Brinda Balakrishnan
23 May 23
4
David R.W. Jayne
23 May 23
4
Joseph P Hagan
23 May 23
4
Daniel Billen
23 May 23
4
GEORGE M MILNE JR
23 May 23
4
R. Hector MacKay-Dunn
23 May 23
4
Jill Leversage
23 May 23
SC 13D/A
ILJIN SNT Co., Ltd.
10 May 23
4
GEORGE M MILNE JR
6 Mar 23
4
Matthew Maxwell Donley
6 Mar 23
4
Joseph M Miller
6 Mar 23
4
Stephen P. Robertson
6 Mar 23
4
Michael Robert Martin
6 Mar 23
4
Scott Michael Habig
6 Mar 23
4
Volker Knappertz
6 Mar 23
4
Peter Greenleaf
6 Mar 23